Lemborexant
Lemborexant is an orexin receptor antagonist used for the treatment of insomnia in adults, particularly difficulties with falling asleep and maintaining sleep. It works by blocking orexin receptors (OX1R and OX2R), reducing wakefulness signalling in the brain and helping regulate the sleep–wake cycle. It is available as oral tablets and is generally taken once nightly, shortly before bedtime, when the patient can allow at least seven hours for sleep. Common side effects include sleepiness, fatigue, headache, and abnormal dreams. Important precautions include the risk of next-day impairment, sleep paralysis, hallucinations, and complex sleep behaviours; it should not be used in patients with narcolepsy and requires caution when combined with alcohol or other central nervous system depressants. Lemborexant should be prescribed under medical supervision, with attention to potential drug interactions and the patient’s sleep pattern.
Lemborexant was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lemborexant, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Lemborexant from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lemborexant, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
